Thompson Siegel & Walmsley’s STAAR Surgical STAA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio STAA Stock Details STAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,000	Closed	-$176K	–	783
2019 Q4	$176K	Buy	+5,000	New	+$165K	﹤0.01%	383

Other funds holding STAA

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Thompson Siegel & Walmsley's STAA Position: Q1 2020 in Review

Thompson Siegel & Walmsley sold out of STAAR Surgical (STAA) in Q1 2020, closing a stake of 5,000 shares — an estimated $176K sold.

Thompson Siegel & Walmsley first reported a position in STAA in Q4 2019 and held it in 1 quarter. The position peaked at $176K in Q4 2019. 160 funds tracked by Wall St. Rank hold STAA as of Q1 2020.

Thompson Siegel & Walmsley reported no remaining STAAR Surgical position as of Q1 2020 after selling out during the quarter.
Thompson Siegel & Walmsley sold 5,000 STAAR Surgical shares in Q1 2020, an estimated $176K.
Thompson Siegel & Walmsley first reported a position in STAAR Surgical in Q4 2019 and held it in 1 quarter.
Thompson Siegel & Walmsley's STAAR Surgical position peaked at $176K in Q4 2019.
160 funds tracked by Wall St. Rank held STAAR Surgical as of Q1 2020.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2020, filed 12 May 2020.